SML3425
Harpagoside
≥98% (HPLC)
别名:
(1S ,4aS ,5R ,7S ,7aS )-1,4a,5,6,7,7a-Hexahydro-4a,5-dihydroxy-7-methyl-7-[[(2E )-1-oxo-3-phenyl-2-propen-1-yl]oxy]cyclopenta[c ]pyran-1-yl β-D-glucopyranoside
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
Quality Level
assay
≥98% (HPLC)
form
powder
optical activity
[α]/D -50 to -30°
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
O1[C@H]([C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O)O[C@@H]2OC=C[C@@]3([C@H]2[C@](C[C@H]3O)(OC(=O)\C=C\c4ccccc4)C)O
InChI
1S/C24H30O11/c1-23(35-16(27)8-7-13-5-3-2-4-6-13)11-15(26)24(31)9-10-32-22(20(23)24)34-21-19(30)18(29)17(28)14(12-25)33-21/h2-10,14-15,17-22,25-26,28-31H,11-12H2,1H3/b8-7+/t14-,15-,17-,18+,19-,20-,21+,22+,23+,24-/m1/s1
InChI key
KVRQGMOSZKPBNS-FMHLWDFHSA-N
Biochem/physiol Actions
Harpagoside is an orally available iridoid glycoside and an active component of Harpagophytum extract with cardioprotective effects. Harpagoside is shown to directly bind to and activate ACE2. Allosterically inhibits ACE2 binding to spike protein and reduces viral entry and lessen SARS-CoV-2 infection. Harpagoside was reported to suppress AP-1, IL-6, COX-1/2, c-FOS, NF-ĸB expression and upregulate BMP2 and Wnt signaling pathways.
Orally available iridoid glycoside that exhibits cardioprotective effects; anti-viral and a direct ACE2 activator
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML3425-25MG | 04065268781210 |
| SML3425-5MG | 04065268781227 |